This novel anti-infective, invented by Orchid Pharma, aims to address the rising threat of antimicrobial resistance (AMR) and has been approved for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP)
Read MoreThe integration is expected to enhance efficiency, reduce errors, and streamline processes, ultimately doubling Urmedz's order processing capacity
Read MoreData suggests that 1.2 million deaths in India are due to antimicrobial resistance (AMR), with an estimated 10 million deaths by 2050
Read MoreThe facility has been granted a Voluntary Action Indicated (VAI) status following an inspection that took place from May 7 to May 17, 2024
Read MoreA study by business consultancy firm Grand View Research has estimated that the global pharma robotics market will expand at a CAGR of 8.7 per cent from 2023 to 2030 to reach USD 357.9 million by the end of this decade
Read MoreStudies suggest that women spend 25 per cent more time in poor health compared to men
Read MoreThe transaction has been executed through the Kotak Strategic Situations Fund II
Read MoreIn a recently released monthly spend data it has been realised that the average Indian household spends almost 5.9 per cent of the monthly spending on health
Read MoreThe investment, in exchange for an undisclosed equity stake, is set to expedite Orbicular's product pipeline development
Read MoreOn an yearly basis, gross profit for FY24 was Rs16,291 million, up 22 per cent from Rs 13,328 million in FY23
Read More